Childrens Plus Multi Symptom Cold

Childrens Plus Multi Symptom Cold Manufacturers

• Best Choice (Valu Merchandisers Company)
  

  ×

  Childrens Plus Multi Symptom Cold | Best Choice (valu Merchandisers Company)

  

  ---

  this product does not contain directions or complete warnings for adult use mL=milliliter shake well before using measure only with dosing cup provided do not use any other dosing device keep dosing cup with product do not give more than 5 times in 24 hours if needed, repeat dose every 4 hours while symptoms last find the right dose on chart below. If possible, use weight to dose, otherwise, use age. Weight (lb) Age (yr) Dose (mL)  48-95 6-11 10 mL  36-47  4-5  do not use unless directed by a doctor under 36 under 4 do not use

  Close
  No Recall

  More Info
• Walgreens
  

  ×

  Childrens Plus Multi Symptom Cold | Remedyrepack Inc.

  

  ---

  ●  Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily.(2.1)

                  O  Small, fragile, or elderly patients, or patients with hepatic insufficiency may be

                       started on 2.5 mg once daily. (2.1)

  ●  Pediatric starting dose: 2.5 mg to 5 mg once daily. (2.2)

  Important Limitation: Doses in excess of 5 mg daily have not been studied in pediatric patients. (2.2)

   

  The usual initial antihypertensive oral dose of amlodipine besylate tablets are 5 mg once daily, and the maximum dose is 10 mg once daily.

  Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine besylate tablets to other antihypertensive therapy.

  Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently.

   

  Angina: The recommended dose for chronic stable or vasospastic angina is 5–10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect.

  Coronary artery disease: The recommended dose range for patients with coronary artery disease is 5–10 mg once daily. In clinical studies, the majority of patients required 10 mg [see Clinical Studies (14.4)].

   

  The effective antihypertensive oral dose in pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients [see Clinical Pharmacology (12.4), Clinical Studies (14.1)].

   

  Close
  No Recall

  More Info
• Dolgencorp, Inc. (Dollar General & Rexall)
  

  ×

  Childrens Plus Multi Symptom Cold | Remedyrepack Inc.

  

  ---

  Gabapentinis given orally with or without food.

  If gabapentindose is reduced, discontinued, or substituted with an alternative medication, this should be done gradually over a minimum of 1 week (a longer period may be needed at the discretion of the prescriber).

  Postherpetic Neuralgia

  In adults with postherpetic neuralgia, gabapentin therapy may be initiated as a single 300-mg dose on Day 1, 600 mg/day on Day 2 (divided BID), and 900 mg/day on Day 3 (divided TID). The dose can subsequently be titrated up as needed for pain relief to a daily dose of 1800 mg (divided TID). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range. Additional benefit of using doses greater than 1800 mg/day was not demonstrated.

  Epilepsy

  Gabapentin is recommended for add-on therapy in patients 3 years of age and older. Effectiveness in pediatric patients below the age of 3 years has not been established.

  Patients >12 years of age: The effective dose of gabapentin is 900 to 1800 mg/day and given in divided doses (three times a day) using 300 or 400 mg capsules. The starting dose is 300 mg three times a day. If necessary, the dose may be increased using 300 or 400 mg capsules, three times a day up to 1800 mg/day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. The maximum time between doses in the TID schedule should not exceed 12 hours.

  Pediatric Patients Age 3 to 12 years: The starting dose should range from 10 to15 mg/kg/day in 3 divided doses, and the effective dose reached by upward titration over a period of approximately 3 days. The effective dose of gabapentin in patients 5 years of age and older is 25 to 35 mg/kg/day and given in divided doses (three times a day). The effective dose in pediatric patients ages 3 and 4 years is 40 mg/kg/day and given in divided doses (three times a day) (see CLINICAL PHARMACOLOGY, Pediatric). Gabapentin may be administered as the oral solution, capsule, or tablet, or using combinations of these formulations. Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study. The maximum time interval between doses should not exceed 12 hours.

  It is not necessary to monitor gabapentin plasma concentrations to optimize gabapentintherapy. Further, because there are no significant pharmacokinetic interactions among gabapentinand other commonly used antiepileptic drugs, the addition of gabapentin does not alter the plasma levels of these drugs appreciably.

  If gabapentin is discontinued and/or an alternate anticonvulsant medication is added to the therapy, this should be done gradually over a minimum of 1 week.

  Dosage in Renal Impairment

  Creatinine clearance is difficult to measure in outpatients. In patients with stable renal function, creatinine clearance (CCr) can be reasonably well estimated using the equation of Cockcroft and Gault:

  for females CCr=(0.85)(140-age)(weight)/[(72)(SCr)]

  for males CCr=(140-age)(weight)/[(72)(SCr)]

  in which age is in years, weight is in kilograms, and SCr is serum creatinine in mg/dL.

  Dosage adjustment in patients ≥12 years of age with compromised renal function or undergoing hemodialysis is recommended as follows (see dosing recommendations above for effective doses in each indication).

  TABLE 6. Gabapentin Dosage Based on Renal Function

  Renal Function Creatinine Clearance (mL/min)
  Total Daily Dose Range
  (mg/day)
  Dose Regimen(mg)
  ≥60
  900 to 3600
  300 TID
  400 TID
  600 TID
  800 TID
  1200 TID
  >30 to 59
  400 to 1400
  200 BID
  300 BID
  400 BID
  500 BID
  700  BID
  >15 to 29
  200 to 700
  200 QD
  300 QD
  400 QD
  500 QD
  700 QD
  15a
  100 to 300
  100 QD
  125 QD
  150 QD
  200 QD
  300 QD
   
  Post-Hemodialysis Supplemental Dose (mg)b
   
  Hemodialysis
  125b
  150b
  200b
  250b
  350b
  a  For patients with creatinine clearance <15 mL/min, reduce daily dose in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 mL/min should receive one-half the daily dose that patients with a creatinine clearance of 15 mL/min receive).
  b  Patients on hemodialysis should receive maintenance doses based on estimates of creatinine clearance as indicated in the upper portion of the table and a supplemental post-hemodialysis dose administered after each 4 hours of hemodialysis as indicated in the lower portion of the table.
  

  The use of gabapentin in patients <12 years of age with compromised renal function has not been studied.

  Dosage in Elderly

  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients.

   

  Close
  No Recall

  More Info
• Freds Inc
  

  ×

  Childrens Plus Multi Symptom Cold | Freds Inc

  

  ---

  this product does not contain directions or complete warnings for adult use mL=milliliter shake well before using measure only with dosing cup provided do not use any other dosing device keep dosing cup with product do not give more than 5 times in 24 hours if needed, repeat dose every 4 hours while symptoms last find the right dose on chart below. If possible, use weight to dose, otherwise, use age. Weight (lb) Age (yr) Dose (mL)  48-95 6-11 10 mL  36-47  4-5  do not use unless directed by a doctor under 36 under 4 do not use

  Close
  No Recall

  More Info
• Select Brand Dist.
  

  ×

  Childrens Plus Multi Symptom Cold | Silarx Pharmaceuticals, Inc

  

  ---

  2.1 Schizophrenia

  Adults

  The recommended starting and target dose for aripiprazole is 10 mg/day or 15 mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole has been systematically evaluated and shown to be effective in a dose range of 10 mg/day to 30 mg/day, when administered as the tablet formulation; however, doses higher than 10 mg/day or 15 mg/day were not more effective than 10 mg/day or 15 mg/day. Dosage increases should generally not be made before 2 weeks, the time needed to achieve steady-state [see CLINICAL STUDIES (14.1)].
  
  Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. These patients were discontinued from those medications and randomized to either aripiprazole 15 mg/day or placebo, and observed for relapse [see CLINICAL STUDIES (14.1)]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.

  Adolescents

  DThe recommended target dose of aripiprazole is 10 mg/day. Aripiprazole was studied in adolescent patients 13 to 17 years of age with schizophrenia at daily doses of 10 mg and 30 mg. The starting daily dose of the tablet formulation in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. Aripiprazole can be administered without regard to meals [see CLINICAL STUDIES (14.1)].Patients should be periodically reassessed to determine the need for maintenance treatment.

  Switching from Other Antipsychotics

  There are no systematically collected data to specifically address switching patients with schizophrenia from other antipsychotics to aripiprazole or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized.

  2.2 Bipolar I Disorder

  Acute Treatment of Manic and Mixed Episodes

  Adults: The recommended starting dose in adults is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. Aripiprazole can be given without regard to meals. The recommended target dose of aripiprazole is 15 mg/day, as monotherapy or as adjunctive therapy with lithium or valproate. The dose may be increased to 30 mg/day based on clinical response. The safety of doses above 30 mg/day has not been evaluated in clinical trials.

  Pediatrics: The recommended starting dose in pediatric patients (10 to 17 years) as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. Recommended dosing as adjunctive therapy to lithium or valproate is the same. Subsequent dose increases, if needed, should be administered in 5 mg/day increments. Aripiprazole can be given without regard to meals [see CLINICAL STUDIES (14.2)].

  Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

  2.7 Dosage Adjustments for Cytochrome P450 Considerations

  Dosage adjustments are recommended in patients who are known CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers (see Table 1). When the coadministered drug is withdrawn from the combination therapy, aripiprazole dosage should then be adjusted to its original level. When the coadministered CYP3A4 inducer is withdrawn, aripiprazole dosage should be reduced to the original level over 1 to 2 weeks. Patients who may be receiving a combination of strong, moderate, and weak inhibitors of CYP3A4 and CYP2D6 (e.g., a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor or a moderate CYP3A4 inhibitor with a moderate CYP2D6 inhibitor), the dosing may be reduced to one-quarter (25%) of the usual dose initially and then adjusted to achieve a favorable clinical response.

  Table 1: Dose Adjustments for Aripiprazole in Patients who are known CYP2D6 Poor Metabolizers and Patients Taking Concomitant CYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducers

  Factors

  Dosage Adjustments for Aripiprazole

  Known CYP2D6 Poor Metabolizers

  Administer half of usual dose

  Known CYP2D6 Poor Metabolizers taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)

  Administer a quarter of usual dose

  Strong CYP2D6 (e.g., quinidine, fluoxetine, paroxetine) or CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)

  Administer half of usual dose

  Strong CYP2D6 and CYP3A4 inhibitors

  Administer a quarter of usual dose

  Strong CYP3A4 inducers (e.g., carbamazepine, rifampin)

  Double usual dose over 1 to 2 weeks

  2.8 Dosing of Oral Solution

  The oral solution can be substituted for tablets on a mg-per-mg basis up to the 25 mg dose level. Patients receiving 30 mg tablets should receive 25 mg of the solution [see CLINICAL PHARMACOLOGY (12.3)].

  Close
  No Recall

  More Info
• Family Dollar (Family Wellness)
  

  ×

  Childrens Plus Multi Symptom Cold | American Amenities, Inc.

  

  ---

  Lather on wet skin and rinse well. Recommended for repeated use

  Close
  No Recall

  More Info